Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.35% | 16.72% | 16.37% | -2.41% | 43.24% |
| Total Depreciation and Amortization | -42.67% | -31.32% | -20.66% | -9.31% | -7.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.42% | 439.86% | 123.69% | 457.14% | -86.73% |
| Change in Net Operating Assets | 44.85% | -1,943.28% | -262.82% | 113.22% | -382.06% |
| Cash from Operations | 26.70% | 21.98% | 9.19% | 28.02% | 17.79% |
| Capital Expenditure | -- | 100.00% | 100.00% | 70.95% | 62.09% |
| Sale of Property, Plant, and Equipment | 973.85% | 775.38% | 775.38% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.91% | 27.64% | 339.17% | 737.43% | 502.77% |
| Cash from Investing | -25.45% | 28.60% | 338.48% | 721.12% | 497.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,531.52% | -12.89% | -50.35% | -99.88% | -99.85% |
| Repurchase of Common Stock | -4,039.42% | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4,064.81% | 181.48% | -13.54% | -99.88% | -99.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.95% | 96.76% | 100.25% | 206.40% | 138.79% |